Zafirlukast: A review of its pharmacology and therapeutic potential in the management of asthma

Drugs

Volumn 55, Issue 1, 1998, Pages 121-144

  Adkins, Julie C ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ERYTHROMYCIN; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; TERFENADINE; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ABDOMINAL PAIN; ASTHMA; BACKACHE; BRONCHITIS; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; EXERCISE; HEADACHE; HUMAN; INFECTION; INFLUENZA; NAUSEA; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACOECONOMICS; PHARYNGITIS; PROVOCATION TEST; RASH; REVIEW; RHINITIS;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; HUMANS; LEUKOTRIENE ANTAGONISTS; TOSYL COMPOUNDS;

EID: 0031983442     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855010-00008     Document Type: Review

References (103)

1. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994; 47 (1): 12-24
2. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995 Jul; 8: 1203-13
3. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997 Jan-Feb; 17 (Pt 2): 22-30
4. Ind PW. Anti-leukotriene intervention: is there adequate information for clinical use in asthma? Respir Med 1996 Nov; 90: 575-86
5. Nathan RA. Anti-leukotriene agents: a new direction in asthma therapy. J Asthma 1996; 33 (6): 353-66
6. Smith LJ. Leukotrienes in asthma: The potential therapeutic role of antileukotriene agents. Arch Intern Med 1996; 156 (19): 2181-9
7. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111 Suppl.: 27S-34S
8. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997; 54(3): 369-84
9. Krell RD. The emergence of potent and selective peptide leukotriene receptor antagonists. Pulm Pharmacol 1989; 2: 27-31
10. Dahlén S-E, Hedqvist P, Hammarström S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980 Dec; 288: 484-6
11. Weiss J, Drazen JM, Coles N. Bronchoconstrictor effects of leukotriene C in humans. Science 1982 Apr; 216: 196-8
12. Griffin M, Weiss J, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983 Feb; 308: 436-9
13. 4, and histamine in normal human subjects. Thorax 1984; 39: 500-4
14. 4. Endothelial contraction. Am J Pathol 1987 Jan; 126: 14-24
15. 4 increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-51
16. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993 Apr; 341: 989-90
17. Krell RD, Dehaas CJ, Lengel DJ, et al. Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICT 204,219 (Accolate™). Ann NY Acad Sci 1994; 744: 289-98
18. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988 Oct; 82: 654-60
19. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141: 993-7
20. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991; 144: 1053-7
21. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989 Mar; 1: 584-7
22. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146: 104-8
23. 4 in bronchoalveolar fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112-9
24. 4, and histamine in asthmatics. Am Rev Respir Dis 1992 Jul; 146: 96-103
25. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996 Aug; 26: 868-79
26. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997 Jan-Feb; 17 (Pt 2): 3-12
27. Dahlén S-E, Dahlén B, Kumlin M, et al. Clinical and experimental studies of leukotrienes as mediators of airway obstruction in humans. In: Dahlén S-E et al., editors. Advances in prostaglandin, thromboxane and leukotriene research. v. 22. New York: Raven Press Ltd, 1994: 155-66
28. Buckner CK, Fedyna JS, Robertson JL, et al. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways. J Pharmacol Exp Ther 1990 Jan; 252: 77-85
29. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219: a peptide leukotriene antagonist. Am Rev Respir Dis 1990 Apr; 141: 978-87
30. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993 Oct; 54: 430-6
31. 4)-induced bronchoconstriction in patients with asthma [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 48
32. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990 Apr; 141: 988-92
33. 4)-induced bronchoconstriction in asthmatic patients receiving inhaled corticosteroids [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 437s
34. Dahlén B, Zetterström O, Björck T, et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994 Feb; 7: 324-31
35. Findlay SR, Barden JM, Easley CB, et al. Effect of the oral leukotriene antagonist. ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992 May; 89: 1040-5
36. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993 Jun; 147 (Pt 1): 1431-5
37. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991 Mar 23; 337: 690-4
38. 4 receptor antagonist. Am Rev Respir Dis 1992 Apr; 145: 746-9
39. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993 Jun; 147 (Pt 1): 1413-8
40. Ostrom N, Bronsky E, Pearlman D, et al. Effects of the leukotriene-receptor antagonist zafirlukast on exercise-induced asthma in pediatric subjects [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 276s
41. Boulet LP, Bai TR, Miller CJ, et al. Effects of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma [abstract no. 1732]. Eur Respir J 1996; 9 Suppl. 23: 272s
42. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma [abstract]. J Allergy Clin Immunol 1993; 93 (Pt 2): 295
43. Israel E, Lavins BJ, Miller CJ, et al. Effect of zafirlukast (20 and 40 mg) on cold-air-induced bronchoconstriction in patients with bronchial asthma [abstract no. P0381]. Eur Respir J 1996; 9 Suppl. 23: 51s
44. Richter K, Specklin P, Koschyk S, et al. Efficacy and duration of action of zafirlukast on cold air-induced bronchoconstriction in patients with asthma [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 419s
45. Lazarus SC, Lavins BJ, Wong HH, et al. Effect of Accolate™ (zafirlukast) on sulfur dioxide (SO2)-induced bronchoconstriction in patients with mild to moderate asthma [abstract]. Allergy 1995; 50 Suppl. 26: 26
46. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993 Jan; 147: 215-7
47. Diaz P, Gonzalez MC, Galleguillos FR, et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis 1989; 139: 1383-9
48. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-57
49. Hulgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol 1996; 98 (1): 1-13
50. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-63
51. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994 Feb; 105: 483-8
52. Aalbers R, De Monchy JGR. Cysteinyl-leukotriene receptor antagonist, bronchoconstriction, and airway hyperreactivity [letter]. Lancet 1991 Aug 17; 338: 445
53. Rosenthal R, Lavins BJ, Hanby LA, et al. Effect of treatment with zafirlukast (Accolate™) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol 1996 Jan; 97(Pt 3): 250
54. Westbroek J, Pasma HR. The effect of inhaled fluticasone propionate (FP) 100 μg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsivess in mild to moderate asthmatics [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 243s
55. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate™ (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma [abstract]. Asthma 95: Theory to Treatment; 15 Jul 1995: 46
56. Calhoun WJ, Williams KL, Simonson SG, et al. Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma [abstract no. 268]. Allergy 1997; 52 Suppl. 37: 90
57. Weiler JM. Exercise-induced asthma: a practical guide to definitions, diagnosis, prevalence, and treatment. Allergy Asthma Proc 1996 Nov-Dec; 17: 315-25
58. National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. IX. Exercise-induced asthma. J Allergy Clin Immunol 1991 Sep; 88: 519-22
59. Hofstra WB, Sterk PJ, Neijens HJ, et al. Short-term treatment with zafirlukast, sodium cromoglycate or placebo in reducing exercise-induced bronchoconstriction in adolescent asthmatics [abstract]. Eur Respir J 1997; 10 Suppl. 25: 220s
60. Zeneca Pharmaceuticals. Zafirlukast prescribing information. Delaware, USA, 1996
61. Zeneca Pharmaceuticals. Zafirlukast product monograph. Cheshire, UK, August 1997
62. Savidge RD, Birmingham BK, Morse JL, et al. Disposition and metabolism of radiolabeled zafirlukast in the mouse, rat, dog and man [abstract]. 7th North American International Society for the Study of Xenobiotics Meeting; 1996 Oct 20-24; San Diego (CA), 391
63. Grimm SW, Stams KR, Aaron EJ. Zafirlukast is a substrate for CYP2C9 and an inhibitor of CYP2C9 and CYP3A in vitro [abstract]. 7th North American International Society for the Study of Xenobiotics Meeting; 1996 Oct 20-24: San Diego (CA), 392
64. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994 Sep; 150: 618-23
65. Vargo DL, Yeh C, Lasseter K, et al. Effect of zafirlukast on prothrombin time and area under the curve of warfarin [abstract]. J Clin Pharmacol 1997; 37: 870
66. Suttle AB, Vargo DL, Wilkinson LA, et al. Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men [abstract no. 584]. Allergy 1997; 52 Suppl. 37: 184
67. c and area under the curve of terfenadine in healthy men [abstract]. J Clin Pharmacol 1997; 37: 870
68. Suttle AB, Birmingham BK, Vargo DL, et al. The pharmacokinetics of zafirlukast and terfenadine after coadministration to healthy men [abstract]. J Clin Pharmacol 1997; 37: 870
69. Morkunas A, Graeme K. Zafirlukast-warfarin drug interaction with gastrointestinal bleeding [abstract]. J Toxicol Clin Toxicol 1997 Aug; 35: 501
70. Quinn DI, Day RO. Appendix B. Guide to clinically more important drug interactions. In: Speight TM, Holford NHG, editors. Avery's drug treatment. 4th ed. Auckland: Adis International, 1997: 1663-99
71. Holgate ST, Anderson KD, Rodgers EM. Comparison of Accolate™(zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients [abstract]. Allergy 1995; 50 Suppl. 26: 319-20
72. Rm) in patients with mild or moderate asthma [abstract]. Asthma 95: Theory to Treatment; 15 July 1995: 46
73. 2-agonists [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 419s
74. Laitinen LA, Zetterström O, Holgate ST, et al. Effects of Accolate™(zafirlukast; 20 mg bd) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day [abstract]. Allergy 1995; 50 Suppl. 26: 320
75. Bateman ED, Holgate ST, Binks SM, et al. A multicentre study to assess the steroid sparing potential of Accolate™ (zafirlukast; 20 mg BD) [abstract]. Allergy 1995; 50 Suppl. 26: 320
76. Virchow JC, Hassall SM, Summerton L, et al. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 437s
77. Micheletto C, Turco P, Dal Negro R. Accolate 20 mg works as steroid sparing in moderate asthma [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A664
78. Virchow JCJ, Hassall SM, Summerton L, et al. Zafirlukast (Accolate™) reduces the impact of asthma in patients taking inhaled corticosteroids [abstract]. 16th International Congress of Allergology and Clinical Immunology; 1997 Oct 22-23; Mexico, Suppl. 4, 243
79. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19 (4): 675-90
80. Spector S, Miller CJ, Glass M. 13-Week dose-response study with Accolate™ (zafirlukast) in patients with mild to moderate asthma [abstract]. Allergy 1995; 50 Suppl. 26: 117
81. Townley R, Glass M, Minkwitz MC. Six-week, dose-escalation study with zafirlukast in patients with mild to moderate asthma [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 288s
82. Howland W, Segal A, Glass M, et al. 6-Week therapy with the oral leukotriene-receptor antagonist, ICI 204,219, in the treatment of asthma [abstract]. J Allergy Clin Immunol 1994 Jan; 93 (Pt 2): 259
83. Nathan RA, Hanby LA, Kylstra JW, et al. Zafirlukast improves symptoms of asthma and quality of life in asthmatic patients with moderate airflow obstruction [abstract]. Eur Respir J 1997 Sep; 10 Suppl 25: 438s
84. Nayak A, Hanby LA, Bonuceelli CM, et al. Zafirlukast improves nasal congestion and asthma symptoms in asthmatic patients [abstract]. 16th International Congress of Allergology and Clinical Immunology; 1997 Oct 22-23; Mexico, Suppl. 4, 241
85. Kemp JP, Glass M, Minkwitz MC. Onset of action of the leukotriene-receptor antagonist, zafirlukast, in patients with asthma [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 288s
86. Bateman ED, Aitchison JA, Summerton L, et al. The early onset of action of zafirlukast (Accolate™) in patients with asthma [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A663
87. Nguyen MH, O'Connor JP, Kylstra JW, et al. Clinical outcomes of zafirlukast treatment in patients with mild to moderate asthma [abstract]. 16th International Congress of Allergology and Clinical Immunology; 1997 Oct 22-23; Mexico, Suppl. 4, 48
88. Barnes NC, Black B, Syrett N, et al. Reduction of exacerbations of asthma in multi-national clinical trials with zafirlukast (Accolate™) [abstract]. Allergy 1996; 51 Suppl. 30: 84
89. Nathan RA, Cohn J, Minkwitz MC. First-dose effect of Accolate™ (zafirlukast) in patients with asthma [abstract]. Ann Allergy Asthma Immunol 1996 Jan; 76: 91
90. Ringdal N, Whitney JG, Summerton L. A comparison of patient preference for treatment with oral zafirlukast or inhaled beclomethasone [abstract]. Eur Respir J 1997; 10 Suppl. 25: 437s
91. Chung KF, Kennelly JC, Summerton L, et al. Compliance with an oral asthma treatment: electronic monitoring of twice daily dosing with zafirlukast [abstract]. 16th International Congress on Allergology and Clinical Immunology; 1997 Oct 22-23; Mexico, Suppl. 4, 241
92. British Asthma Guidelines Coordinating Committee. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: S1-S21
93. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma. 1997: ii-viii, 1-50. National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) Symposium at the 1997 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, NIH Publication No 97-4051A, May 1997
94. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma. 1997: ii-viii, 1-50. National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) Symposium at the 1997 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, NIH Publication No 97-4051A, May 1997
95. Suissa S, Dennis R, Ernst P. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997 Feb 1; 126: 177-83
96. Klim JB, Brown J, Syrett N, et al. Cost impact of reducing exacerbations of asthma in multi-national clinical trials with zafirlukast [abstract no. P0382]. Eur Respir J 1996; 9 Suppl. 23: 52s
97. Food and Drug Administration. Health advisory for new asthma drug. Media Release: [2 pages], 23 Jul 1997, USA
98. FDC Reports-Pink Sheet. Prescriptions Pharmaceuticals and Biotechnology. T&G-7, 16 June 1997, USA: 59
99. National Institutes of Health National Heart Lung and Blood Institute. Global Initiative for Asthma. Asthma Management and Prevention: a practical guide for public health officials and health care professionals, NIH Publication No. 96-3659A, Dec 1995
100. National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma: V. Patient education. J Allergy Clin Immunol 1991 Sep; 88: 460-72
101. National Heart Lung and Blood Institute. Guidelines on the diagnosis and management of asthma: VI. Managing allergy in the asthma patient. J Allergy Clin Immunol 1991 Sep; 88: 473-6
102. Cockcroft DW. Practical issues in asthma management: correct use of inhalation devices. Ann Allergy 1993 Aug; 71: 83-4
103. Larsen JS, Hahn M, Kochevar JW, et al. Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann Allergy 1993 Aug; 71: 103-6